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Abstract 
The plasma anion gap is a frequently used parameter in the clinical diagnosis of a variety 
of conditions. The commonest application of the anion gap is to classify metabolic acidosis into 
those that do or do not leave unmeasured anions in the plasma. While this algorithm is useful in 
streamlining the diagnostic process, it should not be used solely in this fashion. The anion gap 
measures the difference between the unmeasured anions and unmeasured cations and thus 
conveys much more information to the clinician than just quantifying anions of strong acids. In 
this review, the significance of the anion gap is emphasized and several examples are given to 
illustrate a more analytic approach to using the clinical anion gap. These include disorders of low 
anion gap, respiratory alkalosis and pyroglutamic acidosis.  
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Practice  Points 
● The anion gap measures the difference between all unmeasured anions other than HCO3- 
and Cl- , and all unmeasured cations other than Na+. 
● The clinical utility of the anion gap extends far beyond the differential diagnosis of 
metabolic acidosis. 
● It is advisable that the clinician knows the normal range of the anion gap and the assays 
used in measuring Na+ and Cl- in the laboratories supporting their practice. 
● The ability to suspect and recognize that the anion gap is higher or lower than expected in 
a given clinical scenario allows the clinician to have much wider, sharper and more 
sophisticated diagnostic capabilities with information that is presented in routine 
chemistry reports. 
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Research Agenda 
● The role of strong (fully dissociated at plasma pH) ions and weak (titratable with H+ at 
plasma pH) cations and anions in determining in acid-base physiology is often 
unrecognized. This area deserves further data collection in whole organism physiologic 
and pathophysiologic settings. 
● There are vast unexplored territories in how physiologic and pathophysiologic conditions 
alter unmeasured cation and anion concentrations in terms of their generation, 
metabolism, and renal handling. Work in these areas is likely to be fruitful in generating 
novel knowledge in acid-base-electrolyte physiology and clinical medicine. 
● Pyroglutamic acidosis, particularly in milder forms, are more common than realized. The 
pathophysiology of the acquired form of this condition is not clear. Animal models as 
well as carefully performed metabolic studies in humans are much needed to understand 
this potentially life-threatening condition. It is likely that there are other forms of acid-
base disorders that are unrecognized 
. 
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Introduction 
 
 The plasma anion gap is a calculated entity that is utilized frequently in clinical practice 
and is automatically displayed in most routine chemistry reports. The anion gap assumes the 
most central decisive role in the diagnostic algorithms of metabolic acidosis pontificated by most 
textbooks. An implicit axiom is that diagnosticians have secured sufficient expertise in 
interpreting the biologic significance of disturbances in plasma anion gaps and are apt in 
translating this knowledge into clinical actions. The commonest wisdom derived from an 
elevated anion gap is that the addition of acid (H+A-) into the blood has left a footprint because 
the anion (A-) has remained unaltered in the plasma.  While this foremost conclusion is by-and-
large valid, proficiency in the interpretation of anion should extent beyond the ability to arrive at 
this resolution. The scope of the topic precludes an exhaustive discussion of all aspects of the 
plasma anion gap in a single monograph. Selected aspects of the plasma anion gap are reviewed 
to improve the understanding of this simple clinical chemical data. After a brief treatise on the 
physiology of the anion gap, this review will focus on three clinical scenarios; low anion gap, 
anion in respiratory alkalosis, and the increasingly recognized condition of pyroglutamic 
acidosis. 
 
Determinants and Significance of the Plasma Anion Gap 
 
 Although inaccurate, the term anion gap is commonly accepted in everyday clinical 
parlance. As charge balance precludes the existence of any gaps, the more accurate term should 
really be “difference between unmeasured anions and unmeasured cations” which obviously 
lacks the brevity requisite for practical communication. The arbitrary relationship between the 
concentrations of three commonly measured ions (Na+ -Cl- - HCO3-) constitutes the clinical 
“anion gap”. It is important to point out that this entity actually equals  [anionic proteins + 
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inorganic phosphate + sulfate + organic anions] minus [potassium + calcium + magnesium + 
cationic proteins]; all in milliequivalents. Since there are more unmeasured anions than 
unmeasured cations, this term is usually positive. The analysis of the various components has 
been covered in previous reviews (1, 2). 
 
 The classical numeric value of a normal anion gap is considered 12 ± 4 mEq/L based on 
studies conducted in the 1970's, when sodium was determined by flame photometry (based on 
the principle of flame atomic emission spectrometry) and chloride by a colorimetric assay 
(mercuric-nitrate-thyocyanate colorimetric assay). In the early 1980's, ion selective electrodes for 
specific ionic species were introduced for the measurement of serum electrolytes. The difference 
between the ionic concentration in the electrode (known) and the sample creates an electrical 
potential (measured) and the sample ionic concentration can be calculated. This new method has 
caused a shift of the AG from 12 ± 4 mEq/L down to 6 ± 3 mEq/L. (3). It is a worthwhile effort 
for clinicians to be acquainted with the range of normal anion gap and the measuring methods of 
serum sodium and chloride in the laboratories that support their practice. Since there are 
significant inter-individual variations of anion gap, comparing the temporal intra-individual 
changes in anion gap may sometimes be more useful. 
 
 A point made earlier is that an elevated anion gap does not merely reflect the anion A- 
remaining in the plasma after H+A- was added with decomposition of HCO3-. The following 
analysis highlights this notion. Table 1 illustrates one of many lessons one can learn from non-
mammalian physiology. Consider a quintessential anion gap metabolic acidosis- pure lactic 
acidosis- but with two differences. The lactic acidosis though massive, is physiologic and the 
subject is not a human but a diving turtle. Table 1 shows some plasma values in a painted turtle 
before a dive and 150 days later in an anoxic aquatic environment that is completely physiologic 
for this species (4). The resultant prolonged anaerobic metabolism generates a colossal amount 
of lactic acid. The usual analysis by a human biologist (a physician) would take the increase in 
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anion gap (∆ = 34, Table 1) which roughly approximates the fall in bicarbonate (∆ = 45, Table 1) 
and assumes these changes represent the footprint of the lactate added which is equivalent to the 
amount of decomposed bicarbonate. A perusal of the actual measurements clearly demonstrates 
that this analysis is very far from the truth (Table 1). Lactate has actually gone up by 181 mM 
instead of the 34-45 mM predicted from the ∆ anion gap. The decrement in plasma bicarbonate is 
much lower than the addition of lactate because most of the H+ from lactic acid is buffered by the 
carbonate/bicarbonate in the shell rather than plasma buffer. In addition, the cations released 
from the shell into the plasma in exchange for the H+ greatly elevated the unmeasured cations. 
This example illustrates: 1. When buffers outside the extracellular fluid are used, a strong acid 
will not result in equivalence in fall in bicarbonate and rise in the anion gap. 2. Simultaneous 
increase in unmeasured anions and cations has a nullifying effect on each other in terms of the 
value of the anion gap. This exercise serves as caution against the reflex conclusion that the rise 
in anion gap equals the added anion from the invading acid, which equals the fall in bicarbonate. 
For those who share the belief that physicians have much to learn from non-mammalian biology, 
several excellent monographs are available for further reading about physiologic lactic acidosis 
and shell buffering in turtles (4-6).  
 
 The clinical conception and application of the anion gap treats it as a passive parameter in 
the sense that it merely reflects the replacement of HCO3- with an anion from a strong acid. 
Every textbook provides a list of strong acid suspects. Note that not all acid-base physiologists 
share this view. First touched upon by Lawrence Henderson, later fully espoused and presented 
by Paul Stewart in 1983 (7), and in modified forms subsequently (8), is the concept of strong ion 
difference. The strong ion difference hypothesis proposed three independent determinants of 
plasma pH: 1. CO2 tension, 2. Strong ion (fully dissociated ions at physiologic pH) difference 
which is the sum of sodium, potassium, calcium, magnesium minus the sum of chloride, lactate, 
sulphate, ketoanions, and fatty acids. 3. Anions titratible with H+ at physiologic pH such as 
phosphate, albumin, and globulins. Note that the terms listed under 2 and 3 are all reflected in the 
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clinical anion gap equation. From Stewart’s strong ion difference hypothesis, one garners a 
different panorama of the clinical anion gap as this entity assumes the role of an independent 
variable rather than just a sentinel. This review will not expound this alternative position but the 
interested reader can find such discussions by Constable, Boyle, and Baldwin (9, 10). 
 
Approach to a Low Anion Gap 
  
 Whereas the presence of a high anion gap educes the consideration of a differential 
diagnosis by reflex in daily clinical practice, a low anion gap often does not elicit the same 
warning to clinicians and hence often remains either undiscovered or neglected. Furthermore, the 
classic differential diagnosis of a low anion gap has changed since ion selective electrode has 
been introduced. A low anion gap has two utilities. First, it can be an early and sometimes only 
sign of an underlying disease process such as paraproteinemia. Second, a low anion gap can 
mask an underlying high anion gap acidosis and potentially delay intervention. While an increase 
in the anion gap is almost always caused by retained unmeasured anions, a decrease in the anion 
gap can be generated by multiple mechanisms. 
 
 Errors in plasma sodium. Acute dilution of the extracellular fluid with either 
administered or retained hypotonic fluid will theoretically dilute essentially all ions causing a fall 
in the anion gap. However, this type of dilution usually results only in reductions of the anion 
gap of 1 or 2 mEql/L which will hardly move it out of the laboratory normal range. Severe 
hypernatremia can be underestimated by flame photometry due to the non-linear nature of this 
assay. Since the measurement of plasma chloride and bicarbonate remains accurate even at 
increased concentrations, the net result will be a spuriously low anion gap (11, 12). The use of 
sodium-selective electrodes with a larger dynamic range negates this artifact from instrument 
non-linearity. Large non-aqueous volumes in the plasma such as hypertriglyceridemia or 
dysproteinemia  (12-16) can lead to an underestimation of serum sodium especially with flame 
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photometric instruments. However, sodium-selective electrodes are not spared even though the 
sodium activity registered by the sodium electrode is oblivious to the non-aqueous volume. This 
is explained in Figure 1. Automatic aspirators and dilutors prepare the samples and in situations 
with excessive non-aqueous volume in plasma, a smaller than expected plasma volume may be 
aspirated leading to an underestimation of plasma sodium during the back-calculation (Fig 1). In 
the absence of concurrent errors in Cl- and HCO3- measurements, a low anion gap ensures. In 
macroglobulinemia, the error in sodium measurement is proportionate to the level of 
hyperviscosity and can be as high as 40 mEql/L. (17) 
 
 Hypoalbuminemia. At a normal serum pH of 7.4, majority of the plasma proteins are 
anionic. Albumin with an average negative charge of 18 per mole at physiologic pH has been 
shown to be responsible for approximately 75% of the unmeasured anions of the normal anion 
gap (18). A drop in albumin by 10 g/L therefore will cause the anion gap to fall by 
approximately 2.5 mEql/L at constant pH (19, 20). Hypoalbuminemia is probably the 
commonest cause of a clinically relevant lowered anion gap. When both low anion gap and 
hypoalbuminemia are present, it is prudent to ensure that the low anion gap can be quantitatively 
accounted for by the low albumin.  
 
 Errors in plasma chloride. Hypertriglyceridemia can interfere with the colorimetric 
assays of serum chloride measurements due to light-scattering effects and result in marked 
overestimation of serum chloride. Overestimation of serum chloride by lipid interference does 
not occur with ion selective electrode measurements (14). Chloride is normally the only halide 
present in the extracellular fluid in significant concentrations. In acute or chronic bromide 
ingestion, bromide slowly replaces the extracellular chloride mainly because of their differential 
renal tubular handling; the renal tubule seems to reabsorb bromide more avidly than chloride, 
leading to its accumulation in the extracellular fluid (21). Classic sources of bromide were the 
bromide containing over-the-counter sedatives. More recently, pyridostigmin bromide used in 
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the treatment of myasthenia gravis has been reported to cause bromide intoxication. (22). The 
effect of plasma bromide on the anion gap depends on the methods of measurement of chloride 
(Table 1). In the titrametrical measurement assay, both halides react identically and there will be 
no change in the anion gap with high plasma bromide concentration (23). With the colorimetric 
assays, not only are the two halides indistinguishable, bromide usually yields a deeper color than 
chloride giving rise an artificially high chloride concentration resulting in a low anion gap (24). 
With highly selective methods such as voltammetry (25), bromide and chloride does not cross-
react and bromide intoxication presents with an elevated anion gap. By the same mechanism as 
bromide, another halide, iodide, can lead to changes anion gap depending on the assay methods 
(26). Iodide is found in radiologic contrast material expectorants and a number of other 
medications. Patients with renal insufficiency are prone to retain iodide and develop iodinism.  
 
 Non-sodium cations. In addition to displacement of sodium-containing water from serum 
by large amounts of non-sodium–containing paraproteins, some paraproteins can have a net 
positive charge at physiologic pH. This leads to an increase of unmeasured cations and a low 
anion gap (1). Murray et al. found an correlation between the plasma anion gap and paraprotein 
levels and net positive charge on paraproteins in the patients with the lowest anion gaps (27).  Of 
the two commonest immunoglobulins in myeloma, IgG tends to be cationic while IgA tends to 
be anionic at physiologic plasma pH and the disturbances in anion gap seems to correspond 
accordingly (IgG low gap; IgA high gap) (28-30) although this correlation is not always 
invariable (27-32). One convincing piece of evidence supportive of causality is the fact that 
chemotherapy results in simultaneous normalization in paraprotein and anion gap (33). 
Concomitant severe hypercalcemia and hypoalbuminemia are often contributing factors to a low 
anion gap in multiple myeloma.  
 
 Parenteral administration of the now rarely used cationic peptide antibiotic polymyxin B 
can result in hyperchloremia and thereby markedly reduce the serum anion gap. (34). Since the 
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only cation included in the anion gap calculation is sodium, severe hyperkalemia, hypercalcemia, 
hypermagnesemia or lithium intoxication theoretically can also lead to a significantly decreased 
anion gap. Potassium and lithium are fully dissociated while calcium and magnesium exist in 
complexed forms that may or may not contribute cationic charges. For example, albumin bound 
calcium is uncharged but the calcium trivalent citrate soluble complex is a univalent anion. The 
key is to perform the correct calculation when assessing whether these elevated cations can 
quantitatively account for the low anion gap.  
 
The Anion Gap in Respiratory Alkalosis 
 
 Not an uncommon consultation is one requesting evaluation of the following set of 
clinical chemistry data. In mM: Na 138, Cl 103, HCO3- 18, yielding an anion gap of 17. Since the 
HCO3 has fallen about the same degree as the anion gap has risen, the clinician may 
algorithmically default to asking which acid consumed the HCO3- and left the footprint and start 
searching for an anion gap metabolic acidosis. This approach is clearly too restricted. The pitfall 
results from the low plasma bicarbonate from renal compensation of respiratory alkalosis, the 
unknown normal baseline anion gap of that individual, and the slightly elevated anion gap 
encountered in alkalemia.     
  
 Renal compensation in the form of HCO3- excretion to reduce the plasma HCO3- in 
response to a low systemic pCO2 is well documented involving both the proximal (35, 36) and 
distal (37, 38) nephrons. The mechanism by which this happens is unknown although one 
presumes a low pCO2 pervades throughout the body and causes an intracellular alkalosis in the 
renal epithelial cell. Since a fall in plasma HCO3- can potentially rectify the plasma pH 
completely and the kidney is amply able to achieve that, it is unknown why the correction is 
always partial (i.e. plasma pH is never returned to normal). Since these issues are beyond the 
realm of this review, one will settle for the empirical existence of a low plasma HCO3- in our 
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current discussion. We will focus on the plasma anion gap in alkalemia (high plasma pH). Three 
mechanisms can contribute to raising the plasma anion gap in alkalemia. Each may be small in 
magnitude but in combination, these can explain the 3-4 mEq/L rise encountered in clinical 
situations. 
 
 A small but significant elevation of plasma anion gap has been repeatedly observed in 
chronic respiratory alkalosis in humans (39-42). The question remains as to what is the source of 
this alteration. One proposed mechanism is increased plasma lactate generation. This theory is 
based partly on the observation that acute hyperventilation raises plasma lactate levels (43-49). 
The rise in plasma lactate was quite variable in these experimental conditions and in some did 
not persist into the chronic phase. Nonetheless, these observations in conjunction with the 
biochemical evidence of stimulation of glycolysis by high pH have gathered popularity for this 
theory. It is prudent to point out two facts. First, even in the studies quoted above that clearly 
demonstrated elevated anion gap in respiratory alkalosis, it is not always possible to correlate the 
increased anion gap with elevated lactate levels. Second, the stimulation of phosphofructose 
kinase by high pH is well documented in vitro but how much does the glycolytic flux (hence 
lactate generation) actually go up in the intact cell and whole organism is not well established. 
  
 Part of the renal response to acute hypercapnia is bicarbonaturia which mandates mainly 
Na+ and to a lesser extent K+ to accompany the HCO3-in the urine. The loss of NaHCO3 leads to 
extracellular fluid volume contraction and raises plasma albumin concentration. However, if one 
calculates the magnitude of this increase in albumin concentration based on the typical renal 
bicarbonaturic response and acute volume of distribution of HCO3-, the rise in anion gap 
contributed by this component will rarely exceed 1-2 mEq/L. In addition, hyperalbuminemia is 
an inconsistent finding in respiratory alkalosis (39-42). 
 
 The third mechanism by which alkalemia can raise plasma anion gap is via titration of 
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plasma buffers. Albumin is frequently quoted as the main contributor of its relative abundance. 
The situation is far more complex in reality. First is the fact that albumin concentration itself per 
se can impact on plasma acid-base status as mentioned above via the Stewart mechanism (7, 9, 
10). The group of Fencl presented experimental data of this effect and termed it 
“hypoproteinemia alkalosis” (50, 51).  Regardless of this interaction, the question remains as to 
whether charge titration on albumin alone is sufficient to raise the anion gap. Non-denatured 
albumin has an isoelectric point of 5 and has a reasonably steep charge-to-pH relationship 
throughout pH 5-9 (52).  However, the actual contribution of albumin to the change in anion gap 
observed with pH changes is quantitatively less than that predicted from titration of negative 
charges on albumin. Paulson made actual measurements and reviewed the literature and came 
out with an empiric relationship of 0.51 mEq/L of ∆ anion gap for each ∆ pH of 0.1 units (53). 
This further emphasizes the fact that changes in pH alter charges on any anion or cation provided 
these ions do not exist perpetually in dissociation. These are ions in Stewart’s analysis (7) whose 
valence will change in physiologic pH. Two factors determine whether an ion will contribute to 
the pH-dependent change in anion gap: pK and plasma concentration of the ion. A titratable 
substance with a pK of 7.4 will increase its anionic composition by 25% when the pH goes to 7.5 
but if this substance exists in micromolar quantities in the plasma, it will have minimal impact on 
the anion gap. A substance with millimolar concentrations but with a pK of 3 will have no 
appreciable change in its anionic content with the same pH change from 7.4 to 7.5. The ions that 
have clinical impact include phosphate and some organic anions that will increase their valence, 
and positively charged proteins such as some globulins that will decrease their valence as plasma 
pH rise.  Both of these changes will result in an increase in the anion gap. 
 
 
 
Pyroglutamic Acidosis- An Uncommon Severe Anion Gap Metabolic Acidosis  
 
 Although the bulk of the literature on this condition seems fairly recent, this is by no 
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means a new clinical entity. It is most likely that pyroglutamic acidosis is just being recognized 
more frequently now than before. Pyroglutamic acid is natural product found in vegetables, fruits 
and grass and is synonymous with 5-oxoproline, glutimic acid, glutiminic acid, pyrolidone 
carboxylic acid, α-aminoglutaric acid lactam, and perhaps a few other names unbeknownst to the 
authors (Fig 2). It is a strong acid and is a key intermediate metabolite in the γ-glutamyl cycle 
which will be discussed in more detail below. The plethora of aliases partially finds its way to 
the clinical literature so the identical condition is also called 5-oxoprolinuria. Since our interest 
and focus is on the systemic acid-base disturbance rather than the leakage of this substance in the 
urine, we will refer to this condition as pyroglutamic acidosis.  
  
 It is worth a brief mention how a neutral metabolic reaction can lead to metabolic 
acidosis as this pertains not only to pyroglutamic acid but the much more common lactic and 
ketoacidoses. This is illustrated in Figure 3. Metabolic cascades that are neutral may contain 
intermediates with low pK values so they instantly dissociate into H+ and the corresponding 
anion (shown as β-hydroxybutyrate in Fig 3) while transiting through the pathway. The H+ is 
buffered by HCO3- and indeed a momentary “acidosis” develops. However, as the base is 
metabolized, H+ is consumed in equimolar quantity as prior H+ generation and acid-base balance 
is restored with no net gain in acid or base as expected for a neutral metabolic reaction. 
However, two scenarios can convert this neutral reaction to an acid-generating process and 
resultant metabolic acidosis (Fig 3). First is when the generation of intermediate with the low pK 
far exceeds that of the consumption of this intermediate. This dysequilibrium per se can lead to 
accumulation of acid in the extracellular fluid. In addition, if the fate of the intermediate base 
(such as β-hydroxybutyrate in Fig 3) is to go to a sink rather than metabolized, the opportunity of 
consuming the H+ and regenerating the base is foregone. An example of such a sink for the 
example given in Fig 3 is renal excretion of β-hydroxybutyrate as a Na+ and/or K+ salt. These 
two mechanisms can work in conjunction. This scheme can be applied to any metabolic reaction 
with intermediate products with low pKa’s.  
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  To fully understand pyroglutamic acid, one needs to revisit the γ-glutamyl cycle. The γ-
glutamyl cycle has been proposed to facilitate amino acid transport into cells whereas the product 
glutathione has a myriad of functions including the detoxification of reactive oxygen species 
which are particularly important in the mitochondria. Glutathione is a tripeptide (glutamic acid-
cysteine-glycine) found in virtually all cells except perhaps neurons (Fig 2). The characteristic 
peptide bond between glutamate and cysteine is on the γ rather than the usual α-carboxyl group 
that renders the bond resistant to peptidases but an excellent substrate for γ-glutamyl 
transpeptidase. Figure 4 summarizes the γ-glutamyl cycle. Most of the enzymes and reactions in 
this cycle have been confirmed by naturally occurring genetic defects and/or a wide variety of 
inhibitors for each enzymes (55, 56). Glutathione acts a donor of the γ-glutamyl group to a 
variety of amino acids via the action of γ-glutamyltranspeptidase on the cell membrane. The γ-
glutamylaminoacid is taken up into the cell and with release of the γ-glutamyl group as a lactam 
ringed structure, pyroglutamic acid, which is the only strong acid in this cycle. The ring is 
opened to glutamic acid, which then combines with cysteine to form γ-glutamylcycteine. The 
enzyme is γ-glutamylcycteine which is regulated tightly by glutathione levels. γ-
glutamylcycteine acquires a glycine to regenerate glutathione and completes the cycle.  Both 
congenital enzymatic defects as well as acquired conditions can lead to pyroglutamic acidosis 
(see below). 
      
 Regardless of the cause, the clinical syndrome is characterized by acute onset of severe 
metabolic acidosis of widened anion gap. Pyroglutamic acidosis has been known as a 
complication of congenital glutathione or 5-oxoprolinase deficiency (57-61).  Acquired forms of 
pyroglutamic acidosis has been in the literature for more over a decade associated with 
conditions such as dietary glycine deficiency from malnutrition or pregnancy, type 2 diabetes, 
hydrolyzed low lactose formula, and several medications such as antibiotics, vigabatrin, and 
acetaminophen (62-76). In the largest series by Pitt and Hauser, the bicarbonate can be as low as 
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3 mEq/L and anion gap as high as 39 mEq/L (73). The majority of cases showed a temporal 
relationship between the acetaminophen and/or antibiotic administration and the metabolic 
acidosis with subsequent resolution upon cessation of therapy.  
  
 Since this cycle is operative all the time, what is responsible for the sudden massive 
increase in one of its metabolic intermediate from 50-60 µM to more than 30 mM and from its 
baseline 20-25 µmol/kg/30mins flux (77) to 10 fold that amount required to cause the clinical 
syndrome. Mutation in 5-oxoprolinase obviously leads to excess pyroglutamic acid. Glutathione 
synthetase deficiency will decrease glutathione and release the inhibition of γ-glutamylcycteine 
synthetase. The excess γ-glutamylcycteine will have no exit at the glutathione synthetase step but 
will get default to its only other metabolic pathway as a general γ-glutamylcycteine amino acid 
and be converted by γ-glutamylcycteine cyclotransferase to pyroglutamic acid. Glycine 
deficiency will likewise inhibit the glutathione synthetase step and create the same effect. 
Acetaminophen will deplete glutathione and exert a similar effect. It is unclear how beta-lactam 
antibiotics exert its effect but seeing the variety of structures of the various inhibitors of the γ-
glutamyl cycle enzymes (56), it is not surprising that antibiotics may serve as pseudosubstrate 
competitive inhibitors. The same reasoning may apply to vigabatrin. The real incidence of 
increased pyroglutamic acid excretion in patients taking acetaminophen is really unknown but it 
is reasonable to assume that most patients either do not or only have very mild elevations of 
pyroglutamic acid generation. It is highly likely that there are multiple factors involved in the 
generation of the syndrome. There may be polymorphisms in the general population in terms of 
genetic susceptibility and the γ-glutamyl cycle may be impaired at multiple points by 
malnutrition, sepsis, antibiotics and acetaminophen administration. The syndome can be 
reproduced in rodents with high doses of acetaminophen and can be reversed by preventing 
cysteine depletion (78).  
 
 Since most if not all the patients with pyroglutamic acidosis has normal renal function, 
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one would expect that the renal response to this acid load is adequate. A reasonable first 
approximation is to assume this condition to be an overproduction acidosis. Kamel and Halperin 
have pointed out that the renal response to an acute massive elevation in acid generation is 
quantitatively irrelevant because the rapid change does not allow adequate time for the kidney to 
adapt and the magnitude exceed the kidney’s capacity (79, 80). Unfortunately, in none of the 
reports cited above was renal net acid excretion measured. At the moment, one makes the a 
priori assumption that renal acidification is maximized and categorizes pyroglutamic acidosis as 
an overproduction acidosis but the data for this still forthcoming. One can envision that the 
increased production can be coupled with decreased renal net acid excretion. The pyroglutamate 
absorbed from the proximal tubule lumen (81-83) as well as that generated in the proximal 
tubule cell by the γ-glutamyl cycle (84), can both be converted to glutamate by renal 5-
oxoprolinase (85) and glutamate is an intermediate in the pathway for ammoniagenesis between 
glutamine and α-ketoglutarate (79). An oversupply of pyroglutamate in the proximal tubule can 
theoretically suppress ammoniagenesis.  
 
 An interesting comparison can be made between two overproduction acidoses: Hippuric 
acidosis and pyroglutamic acidosis. The hippuric acidosis from toluene intoxication (glue-
sniffing) appears to generate a near but submaximal renal acidification response qualifying it as 
an overproduction acidosis (86). The characteristic of hippuric acidosis is that the plasma anion 
gap typically remains normal (86) or only very slightly elevated.  In contrast, pyroglutamate 
appears to accumulate in the plasma hence disturbing the anion gap.  
 
 While hippurate is processed by a filtration-secretion made in the proximal tubule (87, 
88), the renal handling of pyroglutamate is not as clear but the following analysis supports a 
filtration-reabsorption system (Fig 5). Pyroglutamic acid is taken up from proximal tubule brush 
border membrane vesicles via a Na+-dependent carrier (81-83). Interestingly, pyroglutamic acid 
seems to share transporter mechanisms with the neutral amino acid B0+ rather than anionic amino 
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acids X-A,G system (83). The interaction between pyroglutamic acid and neutral amino acid may 
be more complex than sharing a transporter as pyroglutamic acid appears to stimulate rather than 
compete with the B0+ neutral amino acid transport in the blood brain barrier (89).  Since there is 
no basolateral uptake of pyroglutamic acid from the plasma to the renal tubule via the basolateral 
membrane, the apical Na+-coupled uptake likely results in reabsorption of filtered pyroglutamate 
although the relatively low affinity of 20 mM (83) is unlikely to permit complete uptake.   
 
Conclusion 
 
In this short review, the authors wish to convey and emphasize the concept that the 
clinical anion gap is not a mere reflection of leftover anions of strong acids that has decomposed 
bicarbonate. The utility of the anion gap should exceed way beyond that of the differential 
diagnosis of metabolic acidosis. Once again, emphasis is placed on the fact that the clinical anion 
gap is the difference between the unmeasured anions and the unmeasured cations and any 
numerical analysis of this entity needs to encompass this equation into consideration.  Only by 
exploring all the possible factors that can influence unmeasured cations and unmeasured anions 
can one truly extract useful information from the clinical anion gap. Previously unrecognized or 
poorly described disorders of the anion gap such as pyroglutamic acidosis will continue to 
emerge in clinical medicine. 
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Figure Legends 
 
Figure 1: Hyponatremia from non-aqueous plasma volume. The use of ion-selective electrodes 
that measures Na+ activity theoretically rids the entity of pseudohyponatremia from non-aqueous 
volumes in the plasma if the plasma is never diluted. However, automated aspirator/dilutors 
perpetuates this problem. The top panel depicts the situation in normal plasma. A 10x dilution of 
plasma with water dilutes [Na+] to 14 mEq/L and the back-calculation with a factor of 10 
recapitulates the original plasma [Na+] of 140 mEq/L. The bottom panel depicts plasma with 
normal [Na+] of 140 but an excessive non-aqueous space. The aspirator will take an erroneously 
smaller amount of aqueous plasma and dilute it 10x with water yielding a final [Na+] of 11.2 
mEq/L. Back calculation with the same dilution factor gives a plasma [Na+] of 112 mEq/L. 
 
Figure 2: Structures of pyroglutamic acid and glutathione. Pyroglutamic acid shares the same 
formula (C5H7NO3) as glutamic acid but it contains a lactam ring with a highly dissociable 
carboxyl group. Unlike proline which exist as a zwitterion at pH 7.4, pyroglutamic acid is 
completely dissociated at pH 7.4. Glutathione is a tripeptide of glutamic acid, cysteine and 
glycine but the peptide bond between glutamate and cysteine is on the γ- instead of α-carboxy 
group of glutamate (*) hence the name γ-glutamylcysteinylglycine.. 
 
Figure 3: Metabolic acidosis from a neutral metabolic reaction. A metabolic reaction with 
neutral (acid-base viewpoint) starting substrates and end products such as the breakdown of 
triacylglycerol into carbon dioxide. One intermediate product is a strong acid such as β-
hydroxybutyric (HβHB) acid which dissociates instantaneously in the plasma consuming HCO3- 
which will be regenerated when the β-hydroxybutyrate anion (βHB-) is metabolized. The bottom 
panel shows the two ways by which metabolic acidosis can be generated. 1. The rate of the acid 
generation step exceeds the acid-consumin step. 2. The base is lost from the body before it is 
metabolized. 
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 Figure 4: Gamma-glutamyl cycle and pyroglutamic acidosis. Enzymes of the γ-glutamyl cycle is 
shown in italics. Monogenic defects have been described in four of the enzymes (asterisk). A 
variety of amino acids can acquire a γ-glutamyl group donated by glutathione via γ-
glutamyltransferase. Upon release of the amino acid, the γ-glutamyl group is released as a lactam 
structure which is pyroglutamic acid (or oxoproline). Pyroglutamic acid is a strong 
monocarbolylic acid and is completely dissociated at plasma pH. The ring structure is opened to 
release glutamate by 5-oxoprolinase. Glutathione is regenerated by subsequent addition of 
cysteine and glycine. Since γ-glutamylcycteine is a true γ-glutamyl amino acid, it is a substrate 
for γ-glutamyl cyclotransferase (#) which is a high capacity enzyme. Glutathione shuts off its 
own synthesis not at the immediate proximal step but via negative feedback to inhibit γ-
glutamylcycteine synthetase. 
 
Figure 5: A consideration of two conditions of acid overproduction and a theoretical 
explanation of the changes in the plasma anion gap. Two metabolic acidoses and the renal 
handling of their anions- hippurate (Hp-) and pyroglutamate (pG-). Two assumptions are made. 
Both hippuric acid and pyroglutamic acid consumes a similar amount of HCO3- when added to 
plasma. Renal ammoniagenesis is stimulated but inadequate to regenerate the consumed HCO3- 
hence the acidosis. However the excretion of  Hp- is much more efficient than pG-  resulting in 
normalization of the anion gap in hippuric and not pyroglutamic acidosis. 
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Table 1: Plasma values of Chrysemys picta marginate (diving turtle) 
         
 
 
     Before diving  Anoxic water x 150 days 
 
Concentration in mM 
 
  
Sodium    117    99 
Chloride    73    44 
Bicarbonate    39    5 ∆ = 34 
Anion Gap    5    50 ∆ = 45  
 
 
Unmeasured anions 
Lactate    4    185 ∆ = 181 
 
Unmeasured cations 
Potassium    2    10  
Total Magnesium*   2.6    12    
Total Calcium*   3.7    59 
 
 
 
*Not all in ionized form. Some exist in charged or uncharged soluble complexes so a valence of 2 should not be 
used for conversion from mmole to mEq. Values taken from Reese et al. Resp Physiol 124:43-50, 2000. 
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Table 2: Changes in anion gap in bromide intoxication  
  
 
Sensitivity of assay to halides  Anion gap in bromide intoxication 
 
 
 
Cl- =  Br-     No change 
  
Br- > Cl-     Low anion gap 
 
Cl- >> Br-     High anion gap 
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